An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions.

Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day. 

Syncona Partners LLP

UCL Technology Fund

Fidelity

British Patient Capital

Janus Henderson Investors

Jeito Capital

Monashee Investment Management

Ridgeback Capital

Point72

Fidelity Management and Research Company

SV Health Investors

Tekla Capital Management

Quell Therapeutics

A big shout-out to Afrah Albadri and Maxim Smith for going above and beyond with our company values! We are very proud to have you here at Quell Tx.

We are excited to share that with Quell Therapeutics, we have won the Quris Best Partnership Alliance Award at SCRIP Awards 2023 for our recent collaboration to advance T-regulatory cell therapies in Type 1 diabetes and inflammatory bowel disease. 

This award recognises the importance of both innovative science and the strength of collaboration for pioneering next-generation medicines from the earliest stages. Our partnership continues to drive towards our ambition of cure and remission for people living with chronic immune-mediated conditions.

 #WhatScienceCanDo 

We’re delighted to have received the European Lifestars Award for Deal of the Year (>$500M) last night, for our $2+ billion partnership with AstraZeneca to develop Treg cell therapies for Type 1 Diabetes and Inflammatory Bowel Disease.
 
This award recognises the transformational value of this deal for both the company and wider industry and wouldn't have been possible without the hard work and dedication of our team. 

Congratulations also to the AstraZeneca deal team who partnered with us to get this collaboration together.

🏆 Celebrating our 2023 European Lifestars Awards Winners 🏆

Last night we proudly recognized the achievements of leaders and innovators over the last year within life sciences. We are thrilled to extend our warmest congratulations to all the winners for their outstanding contributions!

🌟 Our Esteemed Award Winners:
Seed Raise of the Year: ARTBIO
Series A Raise of the Year: Complement Therapeutics
Series B Raise of the Year: Hemab Therapeutics
Late Stage Venture Round / Series C+: Apollo Therapeutics
IPO / Listing of the Year: NewAmsterdam Pharma
Post-IPO of the Year: Bicycle Therapeutics
VC Firm of the Year: Forbion
Deal of the Year <€500m: Ariceum Therapeutics and UCB
Deal of the Year >€500m: Quell Therapeutics and AstraZeneca
M&A of the Year: GSK and Bellus Health & Novartis and Chinook Therapeutics, a Novartis Company
Pharma BD Team of the Year: Novo Nordisk
Biotech of the Year: Amolyt Pharma
Medtech of the Year: CorWave
Healthtech of the Year: Seqera
Women-Led Business of the Year: Renee Aguiar-Lucander, CEO, Calliditas Therapeutics
Private Company CEO of the Year: Cedric Ververken, CEO, Confo Therapeutics
Public Company CEO of the Year: Gunilla Osswald, CEO, BioArctic

We are proud to celebrate your accomplishments and look forward to witnessing the continued impact of your work.

Congratulations to all our winners 

#EuropeanLifestarsAwards 

We are delighted that our groundbreaking deal with AstraZeneca has been shortlisted for a second esteemed sector award: the @European Lifestars Awards Deal of the Year (>€500m) recognizes teams and organizations that have executed a truly transformational and high value creating deal for both the company and the wider industry.

The deal, signed in June 2023, combines the respective expertise of the Quell and AZ teams to unlock the potential of our engineered multi-modal engineered Treg cell therapy platform and develop novel treatments for Type 1 Diabetes and Inflammatory Bowel Disease.

Best of luck to all finalists.

Find out more: https://lnkd.in/djRhbbSc 

#Tregcelltherapies #Tregs #T1D #IBD #immunology #immunetolerance

Biopharmaceutical company developing therapies for autoimmune and inflammatory diseases

Sonoma

Company specializing in developing treatments for autoimmune and inflammatory diseases

GentiBio

Biopharmaceutical company focused on T cell therapies for various diseases

Kyverna

Quell Therapeutics is a London, UK based biopharmaceutical company focused on developing transformational and valued therapies for autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation, using modular engineered Treg cell therapies.

Director, Programme Management

Programme Manager

Director of Operations

Principal Scientist/Project Director

Director, Programme Management at Quell Therapeutics

Robert Kallmeier

Head of Cell Processing

Head of Advanced Therapy Production

Senior Immune Therapy Production Scientist

GMP Production Scientist

PhD Student

Laboratory Scientist

Laboratory Technician

Head of Cell Processing at Quell Therapeutics

Laura Fry

Director/Non-Clinical Group Leader

Jenny McGovern

Site Director

Manufacturing Manager

Site Director Quell Therapeutics

Alan Magovern

Associate Director Head Analytical Development

Manager Analytical Development

CMC Analytical Manager

Group Leader Bioassay

Senior Research Scientist

MBA | Head Analytical Development

Julien Browne

Chief Manufacturing Officer

Founder/Principal

VP, Technical Operations

VP, Global Technical Operations (a.i.)

VP, Engineering & Supply Chain

Vice President, Global Supply Chain and Manufacturing

Director, Plant Capacity Management

Associate Director, Cost & Schedule Engineering

Senior Project Manager, Engineering

Biotech Executive | Consultant | Technical Operations | Cell and Gene Therapy

Aaron Vernon

Associate Director - Head of Process Development

Principal Scientist - Process Development

Senior Cell Processing Scientist

Lead Scientist - Phase I/II Clinical Trials

Research Scientist (Industrial Placement)

Aleks Guvenel

Associate Director of Manufacturing Operations

Principal Scientist -cGMP Manufacturing

Senior Production Scientist

Scientist

Tissue Acquisition Coordinator

QC Scientific Officer

Researcher

Sales Representative

Associate Director of Manufacturing Operations at Quell Therapeutics

John Owers

Co-founder & VP Biology

Visiting Senior Lecturer

Senior Lecturer

Lecturer

Postdoctoral Researcher

PhD Researcher

Research Intern

Co-founder & VP Biology at Quell Therapeutics

Marc Martinez-Llordella

Senior Director Translational Medicine

Head of Translational Medicine

Director Translational Platforms

Associate Director Translational Platforms

Group Leader

Senior Scientist

Postdoctoral Research Fellow

Science Presenter

Rupert Kenefeck

Senior Director MSAT

Director, Head Vector Processing

Group Leader & Manager

Senior Scientific Investigator

Senior Director, Manufacturing Science and Technology (MSAT)

Paul Carter

Non Executive Board Member

Head of EU/RoW & Corporate SVP Jazz Pharmaceuticals

Chief Commercial Officer

VP and Global Business Manager, Transplantation

VP and BU Head, Novartis Transplantation and Immunology, Canada

Iain McGill

Director/Team Lead Discovery and New Technologies

Senior Lead Non-Clinical Development

Senior Scientist II

Research Scientist

Research Associate - CAR T-cell Immunotherapy

PhD Cancer Research - CAR T-cell Immunotherapy

Research Assistant

MSc Molecular Medicine

Daniela Penston

Associate Director MSAT

Principal Scientist PD & CMC lead

Senior Scientist / Team lead

Manufacturing Scientist

Laboratory Demonstrator

Junior Research Fellow

Research Trainee

Associate Director | MSAT  | Cell Therapy | ATMP Manufacture

Urvi Thacker

Senior Director Quality Assurance

Independent ATMP Quality Consultant

Vice President Quality

Head of Pharmaceutical Quality Assurance

Validation Team Leader

Quality Assuarance and Compliance Officer

Microbiology Manager

Company Microbiologist

Microbiology Technician

Development Microbiologist

Research Microbiologist

Seb Hodgkin

Chief Medical Officer

Visiting Professor of Immunology

Vice President, Head of Translational Science, Immunology

Executive Director, Head of Early Discovery Biology, I&I TCoE

Senior Director, Translational Medicine

Health Foundation/ Academy of Medical Sciences Clinician Scientist Fellow

Specialist Registrar in Surgery

MRC Clinical Research Training Fellow

Senior House Officer

Pre-registration house officer

Chief Medical Officer, Quell Therapeutics

Luke Devey

Senior Director, Clinical Development

Senior Medical Director, Clinical Development

Medical Director, Clinical Development

Director Clinical Development

Senior Scientist, Clinical Manager

Clinical Scientist

Senior Director, Clinical Development at Quell Tx

Jie Wang

Senior Director, Portfolio Strategy and Alliance Management

Director of Portfolio Strategy and Business Operations

Director Of Business Development

Investment Executive

Project Leader

Data & Analytics Manager, Rare Diseases (BCG Secondment)

Doctoral Degree

Stem Cells Researcher (Amgen Scholarship)

Genomics Researcher (EPFL Scholarship)

Senior Director, Portfolio Strategy and Alliances at Quell Therapeutics

Nikola N.

Director Business Development

Associate Director Business Development

Business Development Manager

Consultant

Intellectual Property Internship

Marketing Strategic Initiatives Internship

Science Policy Adviser Iternship

Biotech Business Development, Licensing & Strategy | 
Quell Therapeutics | MBA

Sophie Brayne

Director of Risk & Financial Control

Global Controls & Compliance (UK SOX)

Director of Risk & Internal Audit

Financial Controller

Risk Manager

Senior Internal Financial Controls Specialist

Assurance Services Controller (Group Internal Audit)

Assurance Services Manager (Group Internal Audit)

Senior Internal Auditor

Audit Senior

Hayley Thomas

Senior Director of Clinical Operation

Director Clinical Operations

Director of Clinical Operations

Senior Project Manager - Professional Services

Early Phase Cancer Clinical Trials Portfolio Manager

Platform Head - Clinical Operations - Data Management

Trial Data Manager

Clinical Data Manager

Clinical Operations Assistant / Clinical Research Associate

Clinical Operations | Leader | Cell & Gene Therapy

David Collin

news impact assignment basic	general	Mar 5, 2024 11:15 AM	3dea0811
public peers	general
news daily refresh	general	Sep 1, 2024 11:00 AM	835ccc00
news processing daily refresh	general	Aug 30, 2024 4:00 AM	da763569
news impact assignment daily	general	Aug 30, 2024 11:59 AM	7f736803
news processing basic	general	Mar 5, 2024 11:15 AM	cb18162c
company summary	general	Aug 30, 2024 7:10 PM	45dac100
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 5, 2024 11:15 AM	6066b476
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 5, 2024 11:15 AM	1d066b4f
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:QUELL-TX

Quell Therapeutics